相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial
Sherene Loi et al.
LANCET ONCOLOGY (2019)
IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) plus nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC).
Peter Schmid et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Randomized phase II study of eribulin mesylate (E) with or without pembrolizumab (P) for hormone receptor-positive (HR plus ) metastatic breast cancer (MBC).
Sara M. Tolaney et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A phase II study of pembrolizumab and capecitabine for triple-negative (TN) and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer (MBC).
Ami N. Shah et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Phase II COLET study: Atezolizumab (A) plus cobimetinib (C) plus paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC).
Adam Brufsky et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial
Leonie Voorwerk et al.
NATURE MEDICINE (2019)
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer A Phase 1 Study
Leisha A. Emens et al.
JAMA ONCOLOGY (2019)
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
S. Adams et al.
ANNALS OF ONCOLOGY (2019)
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
S. Adams et al.
ANNALS OF ONCOLOGY (2019)
Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment
Jessica L. F. Teh et al.
CLINICAL CANCER RESEARCH (2019)
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert M. Samstein et al.
NATURE GENETICS (2019)
Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up A Phase 1b Clinical Trial
Sylvia Adams et al.
JAMA ONCOLOGY (2019)
Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial
Ulrich Keilholz et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
A phase Ia/Ib study of an anti-TIM-3 antibody (LY3321367) monotherapy or in combination with an anti-PD-L1 antibody (LY3300054): Interim safety, efficacy, and pharmacokinetic findings in advanced cancers.
James J. Harding et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
Jiehui Deng et al.
CANCER DISCOVERY (2018)
4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
F. Cardoso et al.
ANNALS OF ONCOLOGY (2018)
Immunotherapy for Breast Cancer is Finally at the Doorstep: Immunotherapy in Breast Cancer
Lucy M. De La Cruz et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
Abstract P5-21-01: Cobimetinib combined with paclitaxel as first-line treatment for patients with advanced triple-negative breast cancer (COLET study): Primary analysis of cohort I
A Brufsky et al.
CANCER RESEARCH (2018)
Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
Hope S. Rugo et al.
CLINICAL CANCER RESEARCH (2018)
Breast cancer immunotherapy using magnetised oncolytic viruses
H. AL-Janabi et al.
EUROPEAN JOURNAL OF CANCER (2018)
Nanofluidic drug-eluting seed for sustained intratumoral immunotherapy in triple negative breast cancer
Corrine Ying Xuan Chua et al.
JOURNAL OF CONTROLLED RELEASE (2018)
PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project
Ming Sound Tsao et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Carsten Denkert et al.
LANCET ONCOLOGY (2018)
Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis
Peter Savas et al.
NATURE MEDICINE (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade
David A. Schaer et al.
CELL REPORTS (2018)
Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types
L. Pare et al.
ANNALS OF ONCOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
TOPACIO/Keynote-162: Niraparib plus pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial
Shaveta Vinayak et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC).
Sibylle Loibl et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Updated efficacy, safety, & PD-L1 status of patients with HR+, HER2-metastatic breast cancer administered abemaciclib plus pembrolizumab.
Sara M. Tolaney et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
David R. Gandara et al.
NATURE MEDICINE (2018)
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Jennifer K. Litton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection
Jonathan A. Trujillo et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Tumor mutational burden is a determinant of immune-mediated survival in breast cancer
Alexandra Thomas et al.
ONCOIMMUNOLOGY (2018)
The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers
Ibrahim Ragab Eissa et al.
CANCERS (2018)
LBA6Durvalumab with or without tremelimumab vs platinum-based chemotherapy as first-line treatment for metastatic non-small cell lung cancer: MYSTIC
N A Rizvi et al.
ANNALS OF ONCOLOGY (2018)
The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer
Francois Bertucci et al.
BRITISH JOURNAL OF CANCER (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives?
Emanuel Nicolas et al.
CANCERS (2018)
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
Luc Y. Dirix et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies
Cariad Chester et al.
BLOOD (2018)
Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status
Yul Ri Chung et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
Intratumoral Delivery of Immunotherapy-Act Locally, Think Globally
M. Angela Aznar et al.
JOURNAL OF IMMUNOLOGY (2017)
cGAS/STING Pathway in Cancer: Jekyll and Hyde Story of Cancer Immune Response
Debojit Bose
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2-Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
George W. Sledge et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Matthew P. Goetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Prognostic value of stromal tumour infiltrating lymphocytes and programmed cell death-ligand 1 expression in breast cancer
Antonio Polonia et al.
JOURNAL OF CLINICAL PATHOLOGY (2017)
CDK4/6 inhibition triggers anti-tumour immunity
Shom Goel et al.
NATURE (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Mark Yarchoan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer
Emma Nolan et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1
Francois Bertucci et al.
CURRENT ONCOLOGY REPORTS (2017)
A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer
David L. Rimm et al.
JAMA ONCOLOGY (2017)
Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients
Florence Koeppel et al.
PLOS ONE (2017)
Targeting immune checkpoints in breast cancer: an update of early results
Cinzia Solinas et al.
ESMO OPEN (2017)
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Nadeem Riaz et al.
CELL (2017)
Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy
Yulian Khagi et al.
CLINICAL CANCER RESEARCH (2017)
Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study
L. Cabel et al.
ANNALS OF ONCOLOGY (2017)
PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression
Shiping Jiao et al.
CLINICAL CANCER RESEARCH (2017)
Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2
Rita Nanda et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Clinical relevance of host immunity in breast cancer: from TILs to the clinic
Peter Savas et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
The PD1/PDL1 axis, a promising therapeutic target in aggressive breast cancers
Francois Bertucci et al.
ONCOIMMUNOLOGY (2016)
Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies
Akira I. Hida et al.
BREAST CANCER RESEARCH AND TREATMENT (2016)
Occurrence and outcome of de novo metastatic breast cancer by subtype in a large, diverse population
Li Tao et al.
CANCER CAUSES & CONTROL (2016)
Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer
George Plitas et al.
IMMUNITY (2016)
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Rita Nanda et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
What does PD-L1 positive or negative mean?
Antoni Ribas et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2016)
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg et al.
LANCET (2016)
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
G. N. Hortobagyi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4
Li Liu et al.
CLINICAL CANCER RESEARCH (2015)
PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients
Hojabr Kakavand et al.
CLINICAL CANCER RESEARCH (2015)
Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive and Triple-Negative Primary Breast Cancers
Carsten Denkert et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer
Nicholas C. Turner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Prognostic and predictive value of PDL1 expression in breast cancer
Renaud Sabatier et al.
ONCOTARGET (2015)
Combinatorial strategies for the induction of immunogenic cell death
Lucillia Bezu et al.
FRONTIERS IN IMMUNOLOGY (2015)
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
S. Loi et al.
ANNALS OF ONCOLOGY (2014)
Association between CD8+T-cell infiltration and breast cancer survival in 12 439 patients
H. R. Ali et al.
ANNALS OF ONCOLOGY (2014)
Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance
Laurence Zitvogel et al.
IMMUNITY (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Impaired IFN-α Production by Plasmacytoid Dendritic Cells Favors Regulatory T-cell Expansion That May Contribute to Breast Cancer Progression
Vanja Sisirak et al.
CANCER RESEARCH (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
A gene expression signature identifies two prognostic subgroups of basal breast cancer
Renaud Sabatier et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden
Theodoros Foukakis et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival
Sylvain Ladoire et al.
JOURNAL OF PATHOLOGY (2011)
Kinome expression profiling and prognosis of basal breast cancers
Renaud Sabatier et al.
MOLECULAR CANCER (2011)
Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy
John Stagg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity
SaeGwang Park et al.
CANCER CELL (2010)
A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers
Krithika N. Kodumudi et al.
CLINICAL CANCER RESEARCH (2010)
B7-H1 expression on non-B and non-T cells promotes distinct effects on T- and B-cell responses in autoimmune arthritis
Keith M. Hamel et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2010)
Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
Carsten Denkert et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
Mojgan Ahmadzadeh et al.
BLOOD (2009)
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Loise M. Francisco et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers
Achim Rody et al.
BREAST CANCER RESEARCH (2009)
Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy
Lei Zhang et al.
CLINICAL IMMUNOLOGY (2008)
Inhibitory B7-family molecules in the tumour microenvironment
Weiping Zou et al.
NATURE REVIEWS IMMUNOLOGY (2008)
An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer
Andrew E. Teschendorff et al.
GENOME BIOLOGY (2007)
Achievements in systemic therapies in the pregenomic era in metastatic breast cancer
Mariantonietta Colozza et al.
ONCOLOGIST (2007)
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
HD Dong et al.
NATURE MEDICINE (2002)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)
分享论文
